CANCER AND LEUKEMIA GROUP B

癌症和白血病 B 组

• 批准号: 3557184
• 负责人: BRIAN LEYLAND-JONES
• 金额: $ 6.01万
• 依托单位: MCGILL UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1982
• 资助国家: 美国
• 起止时间: 1982-07-15 至 1993-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3557184
• 关键词: Abelson leukemia virus; Hodgkin's disease; T lymphocyte; acute leukemia; antigen receptors; autologous transplantation; behavior test; bladder neoplasm; bone marrow transplantation; breast neoplasms; cancer information system; cell growth regulation; cell mediated lymphocytolysis test; colony stimulating factor; combination cancer therapy; cooperative study; cyclosporines; glutamates; glycosyltransferase; health behavior; hematopoietic stem cells; histocompatibility; human subject; human therapy evaluation; interleukin 2; lung neoplasms; lymphoma; messenger RNA; methotrexate; molecular cloning; molecular oncology; monoclonal antibody; neoplasm /cancer chemotherapy; neoplasm /cancer immunology; neoplasm /cancer immunotherapy; neoplasm /cancer radiation therapy; neoplasm /cancer remission /regression; neoplasm /cancer surgery; neoplastic cell; nucleic acid probes; virus RNA

McGill University hospitals have participated in CALGB for the past 25 years. NCI funding for the past five years has permitted the establishment of an effective system of data collection throughout the five participating hospitals which is directed by the McGill Cancer Centre. This has coincided with increased activity at McGill in clinically directed research in neoplastic diseases. As the Group's activity shifted from passive contribution of protocol cases to participation in data evaluation and protocol generation some transient deterioration in case accrual occurred in 1986. This has been recognized and corrected. Accrual is now on target at an annualized rate of 140, due in part to the provision of adequate data collecting staff for the Queen Elizabeth and St. Mary's Hospitals during the past few months. McGill participating in the academic and administrative activities of CALGB has increased markedly over the past 5 years with representation on several core and on most of the administrative committees. We plan to extend our participation in the field of lymphoma and immunology. McGill has major immunology research projects in areas related to CALGB interest. Input into the planned bone marrow transplantation program will be significant as McGill is one of the leading marrow transplant centers in Canada and has had an active program during the past seven years in both autologous and allogeneic marrow transplantation. The many research projects under way at McGill in the oncology field provide a sound basis for increased scientific input into CALGB studies. These are detailed in the Institutional Profile.

麦吉尔大学医院过去曾参加过 CALGB 25 年。 NCI 过去五年的资助使得 建立有效的数据收集体系 由麦吉尔大学指导的五家参与医院 癌症中心。 这与活动增加同时发生 麦吉尔从事肿瘤疾病的临床指导研究。 作为 集团活动从被动贡献协议转向 参与数据评估和协议生成的案例 1986年应计案件出现暂时恶化。 这已得到认可并得到纠正。 应计现已达到目标 年化利率为 140，部分原因是提供 为伊丽莎白女王和圣约翰提供足够的数据收集人员 过去几个月里，圣玛丽医院。 麦吉尔参赛 在 CALGB 的学术和行政活动中 过去 5 年显着增加，代表人数 几个核心和大多数行政委员会。 我们计划扩大对淋巴瘤领域的参与 免疫学。 麦吉尔在以下领域拥有重大免疫学研究项目 与 CALGB 利益相关。 输入计划骨髓 移植计划将具有重要意义，因为麦吉尔是其中之一 加拿大领先的骨髓移植中心，并拥有活跃的 过去七年中在自体和 同种异体骨髓移植。 许多研究项目 麦吉尔大学肿瘤学领域正在进行的研究为 增加对 CALGB 研究的科学投入。 这些都是详细的 在机构简介中。